Peter Hillmen

1.4k total citations
49 papers, 643 citations indexed

About

Peter Hillmen is a scholar working on Genetics, Immunology and Hematology. According to data from OpenAlex, Peter Hillmen has authored 49 papers receiving a total of 643 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Genetics, 28 papers in Immunology and 13 papers in Hematology. Recurrent topics in Peter Hillmen's work include Chronic Lymphocytic Leukemia Research (26 papers), Complement system in diseases (18 papers) and Lymphoma Diagnosis and Treatment (12 papers). Peter Hillmen is often cited by papers focused on Chronic Lymphocytic Leukemia Research (26 papers), Complement system in diseases (18 papers) and Lymphoma Diagnosis and Treatment (12 papers). Peter Hillmen collaborates with scholars based in United Kingdom, United States and Germany. Peter Hillmen's co-authors include Stephen J. Richards, Russell P. Rother, Anita Hill, Richard Kelly, L Arnold, Mary Jane Cullen, Dorothy H. Crawford, Anastasios Karadimitris, Michael A. J. Ferguson and Alastair Baker and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Peter Hillmen

43 papers receiving 629 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Hillmen United Kingdom 11 359 221 200 167 153 49 643
M H Holguin United States 8 481 1.3× 238 1.1× 118 0.6× 201 1.2× 167 1.1× 10 715
Alberto López‐Lera Spain 14 198 0.6× 128 0.6× 291 1.5× 128 0.8× 44 0.3× 30 521
Fiona C. Brown Australia 13 146 0.4× 260 1.2× 99 0.5× 470 2.8× 41 0.3× 27 697
G. M. Shazzad Hossain Prince United States 12 222 0.6× 118 0.5× 33 0.2× 160 1.0× 37 0.2× 22 494
D P Vik United States 13 362 1.0× 140 0.6× 52 0.3× 182 1.1× 24 0.2× 18 546
Arije Ghannam France 11 194 0.5× 78 0.4× 239 1.2× 86 0.5× 22 0.1× 19 444
Dirk Völkel Austria 10 374 1.0× 136 0.6× 54 0.3× 131 0.8× 67 0.4× 13 538
Juo-Chin Yao United States 10 112 0.3× 79 0.4× 34 0.2× 343 2.1× 33 0.2× 17 500
Vanja Karamatic Crew United Kingdom 9 103 0.3× 155 0.7× 60 0.3× 178 1.1× 49 0.3× 18 395
Sharmila Mallya United States 12 133 0.4× 138 0.6× 108 0.5× 495 3.0× 7 0.0× 20 656

Countries citing papers authored by Peter Hillmen

Since Specialization
Citations

This map shows the geographic impact of Peter Hillmen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Hillmen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Hillmen more than expected).

Fields of papers citing papers by Peter Hillmen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Hillmen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Hillmen. The network helps show where Peter Hillmen may publish in the future.

Co-authorship network of co-authors of Peter Hillmen

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Hillmen. A scholar is included among the top collaborators of Peter Hillmen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Hillmen. Peter Hillmen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Latour, Régis Peffault de, Austin Kulasekararaj, David Dingli, et al.. (2025). Anchored Indirect Treatment Comparison Finds Comparable Effects of Pegcetacoplan and Iptacopan in Paroxysmal Nocturnal Haemoglobinuria. European Journal Of Haematology. 115(2). 125–133.
2.
3.
Kelly, Richard J., Morag Griffin, Christopher J. Patriquin, et al.. (2025). Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan. Advances in Therapy. 42(9). 4641–4658.
4.
Hillmen, Peter, et al.. (2024). Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors. International Journal of Molecular Sciences. 25(17). 9477–9477. 5 indexed citations
5.
Holmes, Matthew, Gina B. Scott, Victoria A. Jennings, et al.. (2023). Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells. Molecular Therapy — Oncolytics. 29. 17–29. 4 indexed citations
6.
Munir, Talha, Andy C. Rawstron, Kristian Brock, et al.. (2018). Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy. British Journal of Haematology. 181. 34–35. 1 indexed citations
7.
Griffin, Morag, Talha Munir, Peter Hillmen, et al.. (2017). Thrombosis in Non-Hemolytic Paroxysmal Nocturnal Haemogloinuria. Blood. 130. 1175–1175. 1 indexed citations
8.
Hillmen, Peter, Andy C. Rawstron, Kristian Brock, et al.. (2017). The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory Cll shows acceptable safety and promising early indications of efficacy.. Haematologica. 102. 311–311. 4 indexed citations
9.
Kipps, Thomas J., Tadeusz Robak, Alessandra Tedeschi, et al.. (2016). Improvement in hematologic function, disease burden/symptoms with ibrutinib in older treatment-naive (TN) patients with chronic lymphocytic leukemia (CLL) in phase 3 RESONATE-2 (TM). Journal of the American Geriatrics Society. 64. 1 indexed citations
10.
Hillmen, Peter, Christelle Ferrá, José A. García‐Marco, et al.. (2016). Idelalisib in Combination with Bendamustine/rituximab Improves Overall Survival in Patients with Relapsed/refractory Cll: Interim Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study. Haematologica. 101. 433–433. 2 indexed citations
11.
Eyre, Toby A., Ruth Clifford, Adrian Bloor, et al.. (2015). SINGLE ARM NCRI FEASIBILITY PHASE II STUDY OF CHOP IN COMBINATION WITH OFATUMUMAB IN INDUCTION AND MAINTENANCE FOR PATIENTS WITH NEWLY DIAGNOSED RICHTER'S SYNDROME. Haematologica. 100. 109–109. 2 indexed citations
12.
Parrish, Christopher, Gina B. Scott, G Migneco, et al.. (2015). Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia. Leukemia. 29(9). 1799–1810. 32 indexed citations
13.
Tausch, Eugen, R. Schlenk, Peter Hillmen, et al.. (2014). SF3B1 mutations and outcome in CLL patients treated with chlorambucil (CHL) or ofatumumab-CHL (O plus CHL): results from the phase III study complement 1 (OMB110911). Haematologica. 99. 522–523. 1 indexed citations
14.
15.
Kirwan, Michael, Tom Vulliamy, Anna Marrone, et al.. (2009). Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. Human Mutation. 30(11). 1567–1573. 88 indexed citations
16.
Muus, Petra, Lucio Luzzatto, Bruno Rotoli, et al.. (2007). OP04 Safety and efficacy of the terminal complement inhibitor eculizumab in patients with paroxysmal nocturnal hemoglobinuria: Shepherd Phase III clinical study results. Leukemia Research. 31. S32–S33. 4 indexed citations
17.
Almeida, António, Yoshiko Murakami, D. Mark Layton, et al.. (2006). Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency. Nature Medicine. 12(7). 846–851. 156 indexed citations
18.
Hillmen, Peter. (2004). Future prospects for fludarabine-containing regimens in the treatment of hematological cancers. The Hematology Journal. 5. S76–S86. 4 indexed citations
19.
Moreton, Paul, et al.. (2003). Achieving a MRD negative response after alemtuzumab for CLL is the best predictor for prolonged survival. Blood. 102(11). 39116. 5 indexed citations
20.
Richards, Stephen J., Andy C. Rawstron, & Peter Hillmen. (2000). Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry. 42(4). 223–233. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M H Holguin Breakdown of academic impact, for papers by Alberto López‐Lera Breakdown of academic impact, for papers by Fiona C. Brown Breakdown of academic impact, for papers by G. M. Shazzad Hossain Prince Breakdown of academic impact, for papers by D P Vik Breakdown of academic impact, for papers by Arije Ghannam Breakdown of academic impact, for papers by Dirk Völkel Breakdown of academic impact, for papers by Juo-Chin Yao Breakdown of academic impact, for papers by Vanja Karamatic Crew Breakdown of academic impact, for papers by Sharmila Mallya
Rankless by CCL
2026